XNASRANI
Market cap78mUSD
Jan 08, Last price
1.36USD
1D
-4.90%
1Q
-41.13%
IPO
-87.35%
Name
Rani Therapeutics Holdings Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-34m
L-46.37%
CFO
-51m
L+10.15%
Earnings
Mar 20, 2025
Profile
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 66,921 | 64,763 | |||
Unusual Expense (Income) | |||||
NOPBT | (66,921) | (64,763) | |||
NOPBT Margin | |||||
Operating Taxes | 70 | ||||
Tax Rate | |||||
NOPAT | (66,921) | (64,833) | |||
Net income | (33,970) -46.37% | (63,344) 19.32% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 395 | 316 | |||
BB yield | -0.47% | -0.23% | |||
| Debt | |||||
Debt current | 6,333 | 1,006 | |||
Long-term debt | 25,202 | 30,273 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (17,004) | (67,203) | |||
| Cash flow | |||||
Cash from operating activities | (51,236) | (46,515) | |||
CAPEX | (1,229) | (1,619) | |||
Cash from investing activities | 29,860 | (72,436) | |||
Cash from financing activities | 233 | 29,005 | |||
FCF | (67,293) | (67,324) | |||
| Balance | |||||
Cash | 48,539 | 98,482 | |||
Long term investments | |||||
Excess cash | 48,539 | 98,482 | |||
Stockholders' equity | (60,319) | (1,838) | |||
Invested Capital | 116,579 | 106,056 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 25,505 | 23,817 | |||
Price | 3.32 -43.73% | 5.90 -63.91% | |||
Market cap | 84,677 -39.74% | 140,520 -56.40% | |||
EV | 80,250 | 110,466 | |||
EBITDA | (66,099) | (64,215) | |||
EV/EBITDA | |||||
Interest | 5,085 | 1,071 | |||
Interest/NOPBT | |||||